Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 180 Life Sciences Corp ATNF

Technology Information Technology Services
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR... see more

Recent & Breaking News (NDAQ:ATNF)

180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

Accesswire 10 days ago

180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

Accesswire December 4, 2024

180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration

Accesswire October 31, 2024

180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

Accesswire October 29, 2024

Elray Resources Announces Strategic Sale of Crypto iGaming Technology

GlobeNewswire October 25, 2024

180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform

Accesswire October 16, 2024

180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector

Accesswire October 9, 2024

180 Life Sciences Corp. - Corporate Updates

Accesswire October 3, 2024

180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer

GlobeNewswire September 12, 2024

180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake

GlobeNewswire July 30, 2024

180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

GlobeNewswire July 23, 2024

180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

GlobeNewswire July 2, 2024

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire March 14, 2024

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

GlobeNewswire February 26, 2024

180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives

GlobeNewswire December 4, 2023

180 Life Sciences Announces Review of Strategic Alternatives

GlobeNewswire November 28, 2023

180 Life Sciences Corp. Announces Closing of $3 Million Public Offering

GlobeNewswire August 14, 2023

180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering

GlobeNewswire August 10, 2023

180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

GlobeNewswire August 7, 2023

180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA

GlobeNewswire August 3, 2023